---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-007158"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2026-05-13T20:22:27+00:00"
generated_at: "2026-05-13T21:48:09.748055+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M

## Summary
- Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.
- Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.
- Patient hub enrollment reached ~400 patients; 25% from community settings.
- Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.
- Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access.

## SEC filing metadata
- accession: 0000950103-26-007158
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2026-05-13T20:22:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/0000950103-26-007158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010326007158/dp246650_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-007158
- JSON: https://secwatch.observer/filing/0000950103-26-007158.json
- Plain text: https://secwatch.observer/filing/0000950103-26-007158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.